COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society
Since the first outbreak of coronavirus disease 2019 (COVID-19), ongoing efforts have been made to discover an efficacious vaccine against COVID-19 to combat the pandemic. In most countries, both mRNA and DNA vaccines have been administered, and their side effects have also been reported. The clinical course of COVID-19 and the effects of vaccination against COVID-19 are both influenced by patients’ health status and involve a systemic physiological response. In view of the systemic function of endocrine hormones, endocrine disorders themselves and the therapeutics used to treat them can influence the outcomes of vaccination for COVID-19. However, there are very limited data to support the development of clinical guidelines for patients with specific medical backgrounds based on large clinical trials. In the current severe circumstances of the COVID-19 pandemic, position statements made by clinical specialists are essential to provide appropriate recommendations based on both medical evidence and clinical experiences. As endocrinologists, we would like to present the medical background of COVID-19 vaccination, as well as precautions to prevent the side effects of COVID-19 vaccination in patients with specific endocrine disorders, including adrenal insufficiency, diabetes mellitus, osteoporosis, autoimmune thyroid disease, hypogonadism, and pituitary disorders..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Endocrinology and Metabolism - 36(2021), 4, Seite 757-765 |
| Sprache: |
Englisch ; Koreanisch |
|---|
| Beteiligte Personen: |
Cheol Ryong Ku [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| doi: |
10.3803/EnM.2021.404 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ063509423 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ063509423 | ||
| 003 | DE-627 | ||
| 005 | 20230503030003.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3803/EnM.2021.404 |2 doi | |
| 035 | |a (DE-627)DOAJ063509423 | ||
| 035 | |a (DE-599)DOAJ42cc96b4e4964248bf13e7a02b506f0d | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a kor | ||
| 050 | 0 | |a RC648-665 | |
| 100 | 0 | |a Cheol Ryong Ku |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Since the first outbreak of coronavirus disease 2019 (COVID-19), ongoing efforts have been made to discover an efficacious vaccine against COVID-19 to combat the pandemic. In most countries, both mRNA and DNA vaccines have been administered, and their side effects have also been reported. The clinical course of COVID-19 and the effects of vaccination against COVID-19 are both influenced by patients’ health status and involve a systemic physiological response. In view of the systemic function of endocrine hormones, endocrine disorders themselves and the therapeutics used to treat them can influence the outcomes of vaccination for COVID-19. However, there are very limited data to support the development of clinical guidelines for patients with specific medical backgrounds based on large clinical trials. In the current severe circumstances of the COVID-19 pandemic, position statements made by clinical specialists are essential to provide appropriate recommendations based on both medical evidence and clinical experiences. As endocrinologists, we would like to present the medical background of COVID-19 vaccination, as well as precautions to prevent the side effects of COVID-19 vaccination in patients with specific endocrine disorders, including adrenal insufficiency, diabetes mellitus, osteoporosis, autoimmune thyroid disease, hypogonadism, and pituitary disorders. | ||
| 650 | 4 | |a adrenal insufficiency | |
| 650 | 4 | |a thyroiditis, autoimmune | |
| 650 | 4 | |a covid-19 vaccines | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a osteoporosis | |
| 650 | 4 | |a hypogonadism | |
| 650 | 4 | |a hypopituitarism | |
| 650 | 4 | |a pituitary neoplasms | |
| 653 | 0 | |a Diseases of the endocrine glands. Clinical endocrinology | |
| 700 | 0 | |a Kyong Yeun Jung |e verfasserin |4 aut | |
| 700 | 0 | |a Chang Ho Ahn |e verfasserin |4 aut | |
| 700 | 0 | |a Jun Sung Moon |e verfasserin |4 aut | |
| 700 | 0 | |a Ju Hee Lee |e verfasserin |4 aut | |
| 700 | 0 | |a Eun Heui Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Hyemi Kwon |e verfasserin |4 aut | |
| 700 | 0 | |a Hee Kyung Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Sunghwan Suh |e verfasserin |4 aut | |
| 700 | 0 | |a Sangmo Hong |e verfasserin |4 aut | |
| 700 | 0 | |a Jeonghoon Ha |e verfasserin |4 aut | |
| 700 | 0 | |a Eun Roh |e verfasserin |4 aut | |
| 700 | 0 | |a Jin Hwa Kim |e verfasserin |4 aut | |
| 700 | 0 | |a Mi-kyung Kim |e verfasserin |4 aut | |
| 700 | 0 | |a the Committee of Clinical Practice Guideline of the Korean Endocrine Society |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Endocrinology and Metabolism |d Korean Endocrine Society, 2016 |g 36(2021), 4, Seite 757-765 |w (DE-627)DOAJ000066575 |x 20935978 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2021 |g number:4 |g pages:757-765 |
| 856 | 4 | 0 | |u https://doi.org/10.3803/EnM.2021.404 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/42cc96b4e4964248bf13e7a02b506f0d |z kostenfrei |
| 856 | 4 | 0 | |u http://www.e-enm.org/upload/pdf/enm-2021-404.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2093-596X |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2093-5978 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2021 |e 4 |h 757-765 | ||